
Zydus Lifesciences launched olaparib, a PARP inhibitor branded as IBYRA in India, which provides advanced cancer treatment accessibility. PARP inhibitors, blocking the repair function of PARP proteins in cancer cells, enhance cell death. The drug targets specific genetic mutations in certain cancers, promising tailored treatment. Zydus partnered with MedGenome for comprehensive HRD testing to aid patient selection. Of the 14 lakh new cancer cases in India, nearly 2.75 lakh are breast, ovarian, prostate, or pancreatic cancers, where HRD-positive or BRCA-mutated patients could benefit from IBYRA, a next-gen targeted therapy.
Like
Save
Share